BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27054564)

  • 1. Heparanase and cancer progression: New directions, new promises.
    Arvatz G; Weissmann M; Ilan N; Vlodavsky I
    Hum Vaccin Immunother; 2016 Sep; 12(9):2253-6. PubMed ID: 27054564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
    Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
    Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of heparanase inhibitors in cancer therapy.
    Heyman B; Yang Y
    Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.
    Cassinelli G; Zaffaroni N; Lanzi C
    Cancer Lett; 2016 Nov; 382(2):245-254. PubMed ID: 27666777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.
    Weissmann M; Arvatz G; Horowitz N; Feld S; Naroditsky I; Zhang Y; Ng M; Hammond E; Nevo E; Vlodavsky I; Ilan N
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):704-9. PubMed ID: 26729870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of host heparanase in promoting tumor growth and metastasis.
    Zhang GL; Gutter-Kapon L; Ilan N; Batool T; Singh K; Digre A; Luo Z; Sandler S; Shaked Y; Sanderson RD; Wang XM; Li JP; Vlodavsky I
    Matrix Biol; 2020 Nov; 93():25-42. PubMed ID: 32534153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.
    Barash U; Cohen-Kaplan V; Dowek I; Sanderson RD; Ilan N; Vlodavsky I
    FEBS J; 2010 Oct; 277(19):3890-903. PubMed ID: 20840586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
    Barash U; Lapidot M; Zohar Y; Loomis C; Moreira A; Feld S; Goparaju C; Yang H; Hammond E; Zhang G; Li JP; Ilan N; Nagler A; Pass HI; Vlodavsky I
    J Natl Cancer Inst; 2018 Oct; 110(10):1102-1114. PubMed ID: 29579286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Synthesized Dicarboxylated Oxy-Heparin Efficiently Attenuates Tumor Growth and Metastasis.
    Li L; Barash U; Ilan N; Farhoud M; Zhang X; Vlodavsky I; Li JP
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.
    Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD
    Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
    Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
    J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of heparanase as a therapeutic target in cancer.
    Pisano C; Vlodavsky I; Ilan N; Zunino F
    Biochem Pharmacol; 2014 May; 89(1):12-9. PubMed ID: 24565907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
    Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
    Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression.
    Vlodavsky I; Gross-Cohen M; Weissmann M; Ilan N; Sanderson RD
    Trends Biochem Sci; 2018 Jan; 43(1):18-31. PubMed ID: 29162390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.
    Sanderson RD; Elkin M; Rapraeger AC; Ilan N; Vlodavsky I
    FEBS J; 2017 Jan; 284(1):42-55. PubMed ID: 27758044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds.
    Mohan CD; Hari S; Preetham HD; Rangappa S; Barash U; Ilan N; Nayak SC; Gupta VK; Basappa ; Vlodavsky I; Rangappa KS
    iScience; 2019 May; 15():360-390. PubMed ID: 31103854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of heparanase inhibitors for anti-cancer therapy.
    Miao HQ; Liu H; Navarro E; Kussie P; Zhu Z
    Curr Med Chem; 2006; 13(18):2101-11. PubMed ID: 16918340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparanase, heparin and the coagulation system in cancer progression.
    Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
    Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of heparanase in tumor progression: Molecular aspects and therapeutic options.
    Masola V; Zaza G; Gambaro G; Franchi M; Onisto M
    Semin Cancer Biol; 2020 May; 62():86-98. PubMed ID: 31348993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.
    Ilan N; Elkin M; Vlodavsky I
    Int J Biochem Cell Biol; 2006; 38(12):2018-39. PubMed ID: 16901744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.